141 related articles for article (PubMed ID: 32447931)
1. [Quality of life of 22 patients with type 1 Gaucher disease after enzyme replacement therapy].
Li HM; Zhang RX; Long ZB; Du YL; Chen M; Zhuang JL; Qiu ZQ; Han B
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):287-291. PubMed ID: 32447931
[No Abstract] [Full Text] [Related]
2. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
[TBL] [Abstract][Full Text] [Related]
3. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
Cerón-Rodríguez M; Barajas-Colón E; Ramírez-Devars L; Gutiérrez-Camacho C; Salgado-Loza JL
Mol Genet Genomic Med; 2018 Jan; 6(1):27-34. PubMed ID: 29471591
[TBL] [Abstract][Full Text] [Related]
4. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
5. The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy: results from a retrospective study.
Damiano AM; Pastores GM; Ware JE
Qual Life Res; 1998 Jul; 7(5):373-86. PubMed ID: 9691718
[TBL] [Abstract][Full Text] [Related]
6. Risk of postpartum hemorrhage in multiparous women with Gaucher disease: A call for reconsidering enzyme replacement therapy in all pregnant patients.
Cohen Y; Frydman D; Rotem R; Kofman R; Zimran A; Revel-Vilk S; Grisaru-Granovsky S
J Inherit Metab Dis; 2021 Sep; 44(5):1165-1173. PubMed ID: 33829536
[TBL] [Abstract][Full Text] [Related]
7. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype.
Lo SM; Stein P; Mullaly S; Bar M; Jain D; Pastores GM; Mistry PK
Am J Hematol; 2010 May; 85(5):340-5. PubMed ID: 20425796
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease.
Andrade-Campos M; Alfonso P; Irun P; Armstrong J; Calvo C; Dalmau J; Domingo MR; Barbera JL; Cano H; Fernandez-Galán MA; Franco R; Gracia I; Gracia-Antequera M; Ibañez A; Lendinez F; Madruga M; Martin-Hernández E; O'Callaghan MDM; Del Soto AP; Del Prado YR; Sancho-Val I; Sanjurjo P; Pocovi M; Giraldo P
Orphanet J Rare Dis; 2017 May; 12(1):84. PubMed ID: 28468677
[TBL] [Abstract][Full Text] [Related]
9. Skeletal involvement in Gaucher disease: An observational multicenter study of prognostic factors in the Argentine Gaucher disease patients.
Drelichman G; Fernández Escobar N; Basack N; Aversa L; Larroude MS; Aguilar G; Szlago M; Schenone A; Fynn A; Cuello MF; Aznar M; Fernández R; Ruiz A; Reichel P; Guelbert N; Robledo H; Watman N; Bolesina M; Elena G; Veber SE; Pujal G; Galván G; Chain JJ; Arizo A; Bietti J; Bar D; Dragosky M; Marquez M; Feldman L; Muller K; Zirone S; Buchovsky G; Lanza V; Sanabria A; Fernández I; Jaureguiberry R; Contte M; Barbieri María A; Maro A; Zárate G; Fernández G; Rapetti MC; Donato H; Degano A; Kantor G; Albina R; Á Lvarez Bollea M; Brun M; Bacciedoni V; Del Río F; Soberón B; Boido N; Schweri M; Borchichi S; Welsh V; Corrales M; Cedola A; Carvani A; Diez B; Richard L; Baduel C; Nuñez G; Colimodio R; Barazzutti L; Medici H; Meschengieser S; Damiani G; Nucifora M; Girardi B; Gómez S; Papucci M; Verón D; Quiroga L; Carro G; De Ambrosio P; Ferro J; Pujol M; Castella CC; Franco L; Nisnovich G; Veloso M; Pacheco I; Savarino M; Marino A; Saavedra JL
Am J Hematol; 2016 Oct; 91(10):E448-53. PubMed ID: 27420181
[TBL] [Abstract][Full Text] [Related]
10. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
11. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074
[TBL] [Abstract][Full Text] [Related]
12. Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy.
Stein P; Malhotra A; Haims A; Pastores GM; Mistry PK
J Inherit Metab Dis; 2010 Dec; 33(6):769-74. PubMed ID: 20683668
[TBL] [Abstract][Full Text] [Related]
13. Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy.
Deegan PB; Pavlova E; Tindall J; Stein PE; Bearcroft P; Mehta A; Hughes D; Wraith JE; Cox TM
Medicine (Baltimore); 2011 Jan; 90(1):52-60. PubMed ID: 21200186
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy.
Ersoy M; Pişkinpaşa H
J Pediatr Endocrinol Metab; 2022 Apr; 35(4):519-527. PubMed ID: 35245971
[TBL] [Abstract][Full Text] [Related]
15. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
Giraldo P; Pocoví M; Pérez-Calvo J; Rubio-Félix D; Giralt M
Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
[TBL] [Abstract][Full Text] [Related]
16. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
17. Quality of life related to type 1 Gaucher disease: Spanish experience.
Giraldo P; Solano V; Pérez-Calvo JI; Giralt M; Rubio-Félix D;
Qual Life Res; 2005 Mar; 14(2):453-62. PubMed ID: 15892434
[TBL] [Abstract][Full Text] [Related]
18. Causes of death in 184 patients with type 1 Gaucher disease from the United States who were never treated with enzyme replacement therapy.
Weinreb NJ; Barbouth DS; Lee RE
Blood Cells Mol Dis; 2018 Feb; 68():211-217. PubMed ID: 27816427
[TBL] [Abstract][Full Text] [Related]
19. The role of high density lipoprotein in Type 1 Gaucher disease.
Watad S; Abu-Saleh N; Yousif A; Agbaria A; Rosenbaum H
Blood Cells Mol Dis; 2018 Feb; 68():43-46. PubMed ID: 27876360
[TBL] [Abstract][Full Text] [Related]
20. Gaucher disease: outcome following total hip replacements and effect of enzyme replacement therapy in a cohort of UK patients.
Donaldson J; Khan WS; Tailor H; Hughes DA; Mehta AB; Maruthainar N
Hip Int; 2011; 21(6):665-71. PubMed ID: 22101622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
